-
Product Insights
New![]()
Else-Aktarma GES Solar PV Park
Else-Aktarma GES Solar PV Park is a solar PV project located in Balikesir, Turkey. The project came online in 2017. Empower your strategies with our Else-Aktarma GES Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data...
-
Product Insights
New![]()
Qinghai Ge-ermu Gas Power Plant
Qinghai Ge-ermu Gas Power Plant is a thermal project located in Qinghai, China. The project is owned by Huanghe Hydropower Development Co Ltd. The project came online in 2008. Empower your strategies with our Qinghai Ge-ermu Gas Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the...
-
Product Insights
New![]()
RA Gunes Mardin GES Solar PV Park
RA Gunes Mardin GES Solar PV Park is a solar PV project located in Mardin, Turkey. The project was developed by Apuron Kuloglu Ges & Aku Teknolojisi AS. The project came online in 2020. Empower your strategies with our RA Gunes Mardin GES Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding...
-
Company Insights
New![]()
Innovation and Patenting activity of GE HealthCare Technologies Inc Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of GE HealthCare Technologies Inc Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Bemarituzumab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bemarituzumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Bemarituzumab [FPA-144] is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Tislelizumab (Baizean, Tevimbra) is a humanized monoclonal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zimberelimab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zimberelimab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Zimberelimab (Sepalizumab) is a human monoclonal monospecific antibody...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tirapazamine in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tirapazamine in Gastroesophageal (GE) Junction Carcinomas Drug Details: Tirapazamine is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio) a programmed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Certepetide in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Certepetide in Gastroesophageal (GE) Junction Carcinomas Drug Details: Certepetide (CEND-1) is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.